bioMérieux S.A. (BIM.PA)
- Previous Close
101.40 - Open
101.80 - Bid --
- Ask --
- Day's Range
100.70 - 102.60 - 52 Week Range
84.54 - 108.90 - Volume
97,428 - Avg. Volume
99,249 - Market Cap (intraday)
11.899B - Beta (5Y Monthly) 0.14
- PE Ratio (TTM)
33.46 - EPS (TTM)
3.01 - Earnings Date Apr 9, 2024
- Forward Dividend & Yield 0.85 (0.84%)
- Ex-Dividend Date Jun 7, 2024
- 1y Target Est
113.80
bioMérieux S.A. develops and produces in vitro diagnostic solutions for the diagnosis of infectious diseases in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. The company offers systems that use biological samples, such as blood, saliva, urine, etc. for the diagnosis of infectious diseases, including bacterial infections, parasitic infections, and viral infections; and microbiological control of production or the production environment primarily for food, pharmaceutical, and cosmetic industries. It also provides a suite of software products and services that collect, analyze, and merge various sources of data to make decisions under the BIOMÉRIEUX VISION SUITE name; designs, manufactures, and maintains instruments and software; and designs and manufactures reagents for in vitro diagnostic tests. The company serves clinical and hospital laboratories, physicians, blood banks, vets, and industrial control laboratories. bioMérieux S.A. was formerly known as B-D Mérieux. The company was founded in 1963 and is headquartered in Marcy l'Etoile, France. bioMérieux S.A. is a subsidiary of Institut Mérieux SA.
www.biomerieux.com13,409
Full Time Employees
December 31
Fiscal Year Ends
Sector
Industry
Recent News: BIM.PA
Performance Overview: BIM.PA
Trailing total returns as of 4/24/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: BIM.PA
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: BIM.PA
Valuation Measures
Market Cap
11.98B
Enterprise Value
12.15B
Trailing P/E
33.69
Forward P/E
24.39
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
3.28
Price/Book (mrq)
3.19
Enterprise Value/Revenue
3.31
Enterprise Value/EBITDA
17.33
Financial Highlights
Profitability and Income Statement
Profit Margin
9.73%
Return on Assets (ttm)
6.81%
Return on Equity (ttm)
8.73%
Revenue (ttm)
3.67B
Net Income Avi to Common (ttm)
357.6M
Diluted EPS (ttm)
3.01
Balance Sheet and Cash Flow
Total Cash (mrq)
352.4M
Total Debt/Equity (mrq)
13.83%
Levered Free Cash Flow (ttm)
159.38M
Research Analysis: BIM.PA
Company Insights: BIM.PA
BIM.PA does not have Company Insights